Eve Health Group Limited · ASX:EVE
Eve Health — Shareholder Meeting (May 2025)
12 slides from Eve Health's shareholder meeting presentation, May 29, 2025
Slide 1: Nextract Acquisition Shareholder Meeting
For personal use only NEX T RACT ACQ UI S I T I O N 29 MAY 2025 SHAREHOLDER MEETING REFORMULATING A PROVEN DRUG TARGETING THE $5.3B ERECTILE DYSFUNCTION MARKET ENHANCED SOLUBILITY DESIGNED FOR FASTER ACTION AND HIGHER EFFICACY © EVE HEALTH GROUP 2025
Slide 2: Important Notice and Disclaimer
For personal use only Important Notice and Disclaimer This presentation has been prepared by and issued by Eve Health Group Limited, to assist it in informing interested parties about the Company and its progress. It should not be considered as an offer or invitation to subscribe for or purchase any
Slide 3: Executive Summary
For personal use only Executive Summary Eve Health Overview: Eve Health Group specialises in innovative health solutions, enhancing patient care across various medical sectors. It currently owns Meluka Australia which targets gut health and generated approximately $1.9m in revenue in Australian DTC
Slide 4: The Market Demand for ED Solutions
The Market Demand for ED Solutions For personal use only 322m Phosphodiesterase 5 4 inhibitors (PDE5Is) are the first-line ED therapy. PDE5Is: Viagra, Cialis, Levitra Men globally are projected to be affected by erectile 60% -70% 2 dysfunction in 2025 40% 1 Patients report a positive outcome Men tha
Slide 5: The Nextract Product
The Nextract PRODUCT TIME TO EFFECTIVENESS For personal use only ED Solution Nextract 5 – 15 minutes1 Viagra 30 – 60 minutes (Sildenafil) Cialis 30 – 60 minutes (Tadalafil) Proprietary Solubility Technology: Nextract’s proprietary Levitra 25 – 60 minutes nanoemulsion platform is designed to enhance
Slide 6: Product Pipeline and Development Timeline
For personal use only Product Pipeline and Development Timeline ED Solution Product Product Stability FDA Bioequivalence Study Development 6 Months 6-9 Months Regulatory TGA (SAS-B)1 FDA Application 3 Months 3 - 6 Months Product Marketing Launch Production Product Sales Q1 2025 Q2 2025 Q3 2025 Q4 2
Slide 7: Path to Market
Path to Market For personal use only Regulatory Fast-Tracking in Australia: TGA access pathways for potentially faster commercialisation via (i) SAS-B1, (ii) Authorised Prescriber, (iii) ARTG Export Only. These frameworks enable expedited access for innovative therapies for unmet clinical need. Vita
Slide 8: The Nextract Product: Dysmenorrhea Solution
The Nextract PRODUCT TIME TO Dysmenorrhea Solution For personal use only EFFECTIVENESS Nextract 5 – 15 minutes2 NSAID Addressable Market: Global market size of US$10.9b1 in 2024 (E.g. Ibuprofen, 30 – 60 minutes Naproxen) Proprietary Solubility Technology: Nextract’s formulation is designed Hormonal
Slide 9: Nextract Progress
For personal use only Nextract Progress Nextract: On Track to Deliver Regulatory Approvals, Scalable Manufacturing and First Sales Appointment of Product TGA submission Distribution Partner Target global manufacturer development in for exports Australia markets partner final stages Nextract in discu
Slide 10: Meluka Australia
Meluka Australia Meluka Australia Overview: Meluka Australia is dedicated to delivering premium, taste- For personal use only focused gut health solutions, leveraging the unique benefits of its proprietary Lactobacillus rhamnosus Beebiotic MAP01® strain. Meluka Australia delivered $1.9m of annual re
Slide 11: Directors and Management
For personal use only Directors and Management DAMIAN Dr STUART ROD WOOD GUNZBURG HANNINGTON PROPOSED CSO NON-EXECUTIVE CHAIRMAN MANAGING DIRECTOR Stuart has a PHD specialising in drug Rod has over 25 years of experience Damian is a registered industrial formulation and solubility science. His work
Slide 12: For personal use only
For personal use only 1/245 Churchill Ave, Subiaco WA 6008 +61 8 6465 5500 info@evehealthgroup.com.au W W W . E V E H E A L T H G R O U P . C O M . A U © EVE HEALTH GROUP 2025